The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Extramedullary disease in multiple myeloma: a systematic literature review
Open accessAbstract
Extramedullary involvement (or extramedullary disease, EMD) represents an aggressive form of multiple myeloma (MM), characterized by the ability of a clone and/or subclone to thrive and grow independent of the bone marrow microenvironment. Several different definitions of EMD have been used in the published literature. We advocate that true EMD is restricted to soft-tissue plasmacytomas that arise due to hematogenous spread and have no contact with bony structures. Typical sites of EMD vary according to the phase of MM. At diagnosis, EMD is typically found in skin and soft tissues; at relapse, typical sites involved include liver, kidneys, lymph nodes, central nervous system (CNS), breast, pleura, and pericardium. The reported incidence of EMD varies considerably, and differences in diagnostic approach between studies are likely to contribute to this variability. In patients with newly diagnosed MM, the reported incidence ranges from 0.5% to 4.8%, while in relapsed/refractory MM the reported incidence is 3.4 to 14%. Available data demonstrate that the prognosis is poor, and considerably worse than for MM without soft-tissue plasmacytomas. Among patients with plasmacytomas, those with EMD have poorer outcomes than those with paraskeletal involvement. CNS involvement is rare, but prognosis is even more dismal than for EMD in other locations, particularly if there is leptomeningeal involvement. Available data on treatment outcomes for EMD are derived almost entirely from retrospective studies. Some agents and combinations have shown a degree of efficacy but, as would be expected, this is less than in MM patients with no extramedullary involvement. The paucity of prospective studies makes it difficult to justify strong recommendations for any treatment approach. Prospective data from patients with clearly defined EMD are important for the optimal evaluation of treatment outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Similarly, patients with advanced disease stage (R-ISS stage III) have consistently shown poorer outcomes irrespective of the therapy received4–6,19–22.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [20]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978
Self-citationKumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationIdecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2024850 · Cited by 2,560 · cited 1×
“Published trials of other CAR-T therapies have reported responses in patients with soft-tissue plasmacytomas, but do not report data specifically for patients with EMD [44, 45].”
BackgroundSelf-citationAnti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma.
Raje, N., Berdeja, J., Lin, Y., Siegel, D., Jagannath, S., Madduri, D., Liedtke, M., Rosenblatt, J., Maus, M. V., Turka, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817226 · Cited by 1,730
Cavo, M., Terpos, E., Nanni, C., Moreau, P., Lentzsch, S., Zweegman, S., Hillengaß, J., Engelhardt, M. M., Usmani, S. Z., Vesole, D. H., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30189-4 · Cited by 547
Self-citationVarettoni, M., Corso, A., Pica, G.-M., Mangiacavalli, S., Pascutto, C., & Lazzarino, M. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp329 · Cited by 489
Usmani, S. Z., Heuck, C. J., Mitchell, A., Szymonifka, J. D., Nair, B. P., Hoering, A., Alsayed, Y. M., Waheed, S., Haider, S., Restrepo, A., et al. (2012) · Haematologica · doi:10.3324/haematol.2012.065698 · Cited by 395
Self-citationBladé, J., de Larrea, C. F., Rosiñol, L., Cibeira, M. T., Jiménez, R., & Powles, R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.9290 · Cited by 388
Self-citationde Larrea, C. F., Kyle, R. A., Durie, B. G. M., Ludwig, H., Usmani, S. Z., Vesole, D. H., Hájek, R., Miguel, J. F. S., Sezer, O., Sonneveld, P., et al. (2012) · Leukemia · doi:10.1038/leu.2012.336 · Cited by 384
Self-citationCaers, J., Paiva, B., Zamagni, E., Leleu, X. P., Bladé, J., Kristinsson, S. Y., Touzeau, C., Abildgaard, N., Terpos, E., Heusschen, R., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0549-1 · Cited by 338
Self-citation
Cited by
Sorted by citations
Items 101–200 of 319
Hashmi, H., Sebastian, T., Rajeeve, S., Farzana, T., Firestone, R. S., Jurgens, E., Miller, K. C., Maura, F., Lesokhin, A., Tan, C., et al. (2026) · Blood Cancer Journal · doi:10.1038/s41408-026-01494-y · Cited by 4
Self-citationZHANG, X., ZHOU, Z., WANG, J., HAN, M., LIU, H., Zang, M., Liu, J., LU, J., ZHANG, J., ZHANG, G., et al. (2024) · Biocell · doi:10.32604/biocell.2023.046640 · Cited by 3
Trenker, C., Görg, C., Burchert, A., Westhoff, C. C., Zadeh, E. S., Dietrich, C. F., Findeisen, H., & Mann, C. (2025) · Journal of Ultrasonography · doi:10.15557/jou.2025.0015 · Cited by 3
Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas
Štork, M., Ševčı́ková, S., Jelı́nek, T., Minařík, J., Radocha, J., Pika, T., Pospíšilová, L., Špıčka, I., Štraub, J., Pavlíček, P., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10102535 · Cited by 3
Jiffry, M. Z. M., Ahmed-khan, M. A., Rangsipat, N., Galligani, L., & Torre, C. D. L. (2022) · Cureus · doi:10.7759/cureus.32600 · Cited by 3
Kikuchi, T., Tsukada, N., Kunisada, K., Nomura‐Yogo, M., Oda, Y., Sato, K., Takei, T., Ogura, M., Abe, Y., Suzuki, K., et al. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05432-x · Cited by 3
Sakashita, M., Sahara, N., Aoki, J., Matsunaga, T., Kobayashi, S., Kitahara, S., Fujii, T., & Ohno, N. (2024) · Oncology Letters · doi:10.3892/ol.2024.14381 · Cited by 3
Mele, G., Derudas, D., Conticello, C., Barilà, G., Gentile, M., Rocco, S., Palmieri, S., Palazzo, G., Germano, C., Reddiconto, G., et al. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05811-y · Cited by 3
Eskelinen, V., Nivakoski, E., Launonen, K., Partanen, A., Kakko, S., & Kuusisto, M. E. L. (2024) · Hematology Reports · doi:10.3390/hematolrep16030051 · Cited by 3
Springer, A. D., Wang, R., Wang, J., Du, Q., Pi, W., Nguyen, A. Q., Li, X., Khasanov, A. B., Zhu, T., Yan, Z., et al. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0413 · Cited by 4
DUBR/miR-17-3p/TFRC/HO-1 Axis Promotes the Chemosensitivity of Multiple Myeloma
Guo, T., Zhang, F., Wang, H., He, L., Xia, M., & Niu, X. (2025) · Critical Reviews in Eukaryotic Gene Expression · doi:10.1615/critreveukaryotgeneexpr.2024056835 · Cited by 3
Proteomic Alteration in the Progression of Multiple Myeloma: A Comprehensive Review
Ismail, N. H., Mussa, A., Al‐Khreisat, M. J., Yusoff, S. M., Husin, A., & Johan, M. F. (2023) · Diagnostics · doi:10.3390/diagnostics13142328 · Cited by 5
A Case of Extramedullary Plasmacytoma in Both Maxillary Sinuses
Seo, M., Park, J.-H., Kim, S., Choi, K. U., & Cho, K. (2023) · Journal of rhinology · doi:10.18787/jr.2023.00032 · Cited by 2
Orbital Myeloma and Plasmacytoma: An Australian Study
Xiong, J., Tong, J. Y., Hyer, J. N., O’Donnell, B., Selva, D. N., Hardy, T. G., McNab, A. A., Sullivan, T. J., Taylor, S. F., Figueira, E. C., et al. (2024) · Ophthalmic Plastic and Reconstructive Surgery · doi:10.1097/iop.0000000000002777 · Cited by 2
Siegfried, C., Amarapala, M., Leleu, X. P., & Fusfeld, L. (2025) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s498848 · Cited by 2
Kamboj, I., Habib, A., Chang, D., Rashid, A., Vegel, A. J., Graf, K., Struble, E., Mushtaq, M., Mahmoudjafari, Z., Green, K., et al. (2025) · Clinical Lymphoma, Myeloma & Leukemia · doi:10.1016/j.clml.2025.09.015 · Cited by 2
Wu, M., Shi, S., Guo, Y. S., Yu, M., Sun, R., Xia, M., Yang, Y., & Cui, X. K. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1723537 · Cited by 2
Afrough, A., Dima, D., Razzo, B. M., Goel, U., Sannareddy, A., Pasvolsky, O., Vazquez-Martinez, M. A., Ferreri, C. J., Banerjee, R., Khouri, J., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01414-6 · Cited by 6
Voorhees, P. M., Kumar, S. K., Usmani, S. Z., Ye, J. C., Cohen, Y. C., Scott, E., Carson, R. L., Heuck, C. J., Gan, R. W., Ackerman, B., et al. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06705-3 · Cited by 2
Self-citationKaczmarek, S., Jo, D., Ghaziasgar, S., Marr, B., Berton, S., Wang, L., Ghahroudi, M. A., Jang, M., Visram, A., McComb, S., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.218235 · Cited by 2
Jin, Y., Cheng, X., Zhang, X., Shi, Q., Zhu, Y., Li, J., Fan, L., & Chen, L. (2026) · Blood Advances · doi:10.1182/bloodadvances.2025018945 · Cited by 2
Mondal, S., Becker, N. J., Huo, Y., Zhang, P., Johnson, T. S., Landgren, O., Coffey, D. G., Walker, B. A., & Liu, E. (2026) · Biomedicines · doi:10.3390/biomedicines14071556 · Cited by 2
Relapsed multiple myeloma with gastric and pancreatic extramedullary plasmacytomas
Lin, H. H., Lin, Y.-C., Chen, J.-H., & Wang, Y.-C. (2023) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2023.01.001 · Cited by 2
Boyapati, N., & Trivedi, A. (2023) · Journal of Surgical Case Reports · doi:10.1093/jscr/rjad268 · Cited by 2
Ji, J., Guo, R., Ma, J., Cui, Y., Li, Y., Sun, Z., Li, J., Fan, L., & Qu, X. (2023) · Clinica Chimica Acta · doi:10.1016/j.cca.2023.117497 · Cited by 2
Paraskeletal plasmacytoma presenting as a chest wall mass
Mallik, S., Datta, A., & Mohapatra, D. (2023) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2023.2637 · Cited by 2
Veisi, A., Daneshvar, K., Hooshmandi, S., Najafi, M., Torbati, P. M., & Hassanpour, K. (2024) · Case Reports in Ophthalmology · doi:10.1159/000538120 · Cited by 2
[Consensus for the diagnosis and management of extramedullary plasmacytoma in China(2024)].
(2024) · PubMed Central · doi:10.3760/cma.j.cn121090-20231107-00253 · Cited by 2
Nasal cavity extramedullary plasmacytoma: literature review and clinical experience
Vivekanand, A., & Tara, N. (2024) · Romanian Journal of Rhinology · doi:10.2478/rjr-2024-0012 · Cited by 2
Proteasome and PARP1 dual-target inhibitor for multiple myeloma: Fluzoparib
Deng, K., Li, Q., Lu, L., Wang, L., Cheng, Z., & Wang, S. Z. (2024) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2024.101781 · Cited by 2
Risk stratification in multiple myeloma – A review and update
Das, N., & Gupta, R. (2024) · Annals of the National Academy of Medical Sciences (India) · doi:10.25259/anams-2023-1-7-(820 · Cited by 2
Review of whole-body magnetic resonance imaging in multiple myeloma
Perillo, T., Giorgio, C., Fico, A., Perrotta, M., Serino, A., Cuocolo, R., & Manto, A. (2024) · Japanese Journal of Radiology · doi:10.1007/s11604-024-01635-y · Cited by 2
Kumar, S., Mazloom, A., Carter, M., Manisha, F., Polski, J. M., & Alkharabsheh, O. A. (2024) · Journal of Respiration · doi:10.3390/jor4030016 · Cited by 2
FDG PET/CT in Cutaneous Involvement of Plasmablastic Plasma Cell Myeloma
Mohamed, P., Stuart, S., Vergara-Lluri, R., & Colletti, P. M. (2024) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000005584 · Cited by 2
Spleen Involvement at Diagnosis of Multiple Myeloma: A Case Report and Literature Review
Fiorini, A., Chavez, M. G., Panichi, V., Dell’Aquila, M., Ranucci, V., Remotti, D., Tarnani, M., Montanaro, M., Latagliata, R., & Andriani, A. (2025) · Cancer Reports · doi:10.1002/cnr2.70160 · Cited by 2
Chalopin, T., Cellerin, E., Demarquette, H., Pieragostini, A., Sonntag, C., Jaquet, C., de Wyngaert, Z. V., Rumpler, A., Roussel, M., Labouré, G., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01365-y · Cited by 2
Hiraga, E., Yamai, T., Ikezawa, K., Kawamoto, Y., Hirao, T., Higashi, S., Urabe, M., Kai, Y., Takada, R., Nakabori, T., et al. (2023) · Clinical Case Reports · doi:10.1002/ccr3.7190 · Cited by 2
Hoarseness as the initial presentation of multiple myeloma
Colebunders, J., Hellemans, S., Ahmed, M., Libbrecht, S., & de Bruijn, S. (2023) · Clinical Case Reports · doi:10.1002/ccr3.7322 · Cited by 2
Adam, Z., Pour, L., Krejčí, M., Zeman, D., Vlčková, E., Krtička, M., Šlampa, P., Štěpánková, S., Romanová, G., Adamová, Z., et al. (2022) · Onkologie · doi:10.36290/xon.2022.054 · Cited by 1
Kuric, M., Beck, S., Schneider, D., Rindt, W., Evers, M., Meißner-Weigl, J., Zeck, S., Krug, M., Herrmann, M., Hartmann, T. N., et al. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0411 · Cited by 2
Kang, H. (2024) · Acta Radiologica Open · doi:10.1177/20584601241246105 · Cited by 1
Kavgacı, G., Köksal, B., Arık, Z., Barışta, İ., & Akın, S. (2024) · Plasmatology · doi:10.1177/26348535241277632 · Cited by 1
18F-FDG PET/CT Imaging of Cutaneous and Intramuscular Multiple Myeloma
Lippold, B., & Jahromi, A. H. (2024) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000005579 · Cited by 1
Mudawi, D., Al-Mashdali, A. F., Tawalbeh, A., Szabados, L., Soliman, D. S., & Fareed, S. (2025) · Case Reports in Oncology · doi:10.1159/000545930 · Cited by 1
Chen, F., Wang, Y., Huang, Z., Qi, M., & Chen, H. (2025) · World Journal of Surgical Oncology · doi:10.1186/s12957-025-03851-w · Cited by 1
Alhayek, B., Malone, X., Khan, A., Gummalla, R., & Brink, R. (2025) · Cureus · doi:10.7759/cureus.85455 · Cited by 1
González-Resina, R., Rodríguez-Carpio, R. R., & Molias, A. C. G. (2025) · Medicina Clínica · doi:10.1016/j.medcli.2025.107049 · Cited by 1
Pulmonary plasma cell disorders: histopathology, diagnosis, and clinical perspectives
Pezzuto, F., Fiorentù, G., Castelli, G., Zanella, S., Giraudo, C., Tinè, M., & Calabrese, F. (2025) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-025-04213-3 · Cited by 1
Guo, Y.-H., Tian, Y., Huang, J.-W., Liu, A., & Yang, M.-F. (2025) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000002059 · Cited by 1
Purcell, E., Dowling, P., O’Gorman, P., & Bazou, D. (2025) · Blood Reviews · doi:10.1016/j.blre.2025.101360 · Cited by 1
Bilateral breast plasmacytomas in a male patient with relapsed multiple myeloma: A case report
Eņǵele, I., Zablocka, T., Asere, E., & Eglītis, J. (2025) · Radiology Case Reports · doi:10.1016/j.radcr.2025.11.054 · Cited by 1
Swain, R. N., Wadhera, S., Jandial, A., Singh, C., Jain, A., Prakash, G., Khadwal, A., & Malhotra, P. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.02.010 · Cited by 1
Kondo, Y., Nakabeppu, S., Yano, H., Ishitsuka, K., Urakado, T., Fujiwara, Y., Yamamoto, M., Karube, K., & Komohara, Y. (2026) · Medical Molecular Morphology · doi:10.1007/s00795-026-00460-8 · Cited by 1
Takakuwa, T., Ohta, K., Tanada, Y., Okayama, Y., & Hino, M. (2026) · Annals of Hematology · doi:10.1007/s00277-026-07011-2 · Cited by 1
Li, X., Liu, C., Niu, S., Li, R., Gao, S., Cui, R., Wang, J., Qi, Y., Li, J., & Deng, Q. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08302-y · Cited by 1
McAuley, N., McAvera, R. M., Bong, D., Donnelly, L., Cymer, I., Brennan, M., Fay, J., Hudson, L., Quinn, J., Glavey, S. V., et al. (2026) · European Journal Of Haematology · doi:10.1111/ejh.70225 · Cited by 1
Lee, A. R. Y. B., Wong, H., Lim, C.-Y., de Mel, S., Ooi, M. G., Chng, W., Soon, Y. Y., & Soekojo, C. (2026) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2026.06.001 · Cited by 1
Harzer, M., Gross-Fengels, N.-O., Melzer, F., Molwitz, I., Kosch, R., Al-Bazaz, M., Artzenroth, J., Cords, L., Bartke, L., Kamili, A., et al. (2026) · Annals of Hematology · doi:10.1007/s00277-026-07118-6 · Cited by 1
Xiao, A. H., Zanwar, S., Lin, Y., Kapoor, P., Abdallah, N. H., Baudi, F. K., Binder, M., Dispenzieri, A. A., Dingli, D., Gertz, M. A., et al. (2026) · Blood Advances · doi:10.1182/bloodadvances.2026020668 · Cited by 1
Leitner, T., Oelschläger, L., Mosquera, F. H., Schaefers, C., Leypoldt, L. B., Weisel, K. C., von Bubnoff, N., Rückert, M., Kimmich, C., Ahmed, H., et al. (2026) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2026.2699285 · Cited by 1
Adoptive Immunotherapy and High-Risk Myeloma
Duane, C., O'Dwyer, M. E., & Glavey, S. V. (2023) · Cancers · doi:10.3390/cancers15092633 · Cited by 1
Polski, A. G., Marquez, J. R., & McQuiston, S. A. (2023) · Cureus · doi:10.7759/cureus.43040 · Cited by 1
Improving Automatic Segmentation of lymphoma with Additional Medical Knowledge Priors
Liu, L., Hou, B., Nag, M. K., Liu, J., Hasani, N., Shen, T. C., Zhu, Y., Saboury, B., Xiao, J. Z., & Summers, R. M. (2023) · IEEE International Symposium on Biomedical Imaging (ISBI) · doi:10.1109/isbi53787.2023.10230634 · Cited by 1
Plasmablastic transformation of multiple myeloma post-autologous hematopoietic stem cell transplant
Akbar, N. A. N., Hassan, M. N., Iberahim, S., Saidin, N. I. S., Roslan, W., Halim, N. A. I. A., Abdullah, A. D., Hanafi, H. H. W., Shukri, N. D. M., & Adzahar, S. (2023) · Biomedical Research and Therapy · doi:10.15419/bmrat.v10i8.820 · Cited by 1
Dawd, D., Kapur, S., & Kotchetkov, R. (2024) · Case Reports in Oncology · doi:10.1159/000536675 · Cited by 1
Sgherza, N., Curci, P., Carlo, G. D., Grande, D., Capozzi, A., Ingravallo, G., Marco, L. D., Ferreri, P., & Musto, P. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2364049 · Cited by 1
Li, E. W., Jones, E., Bryant, C. E., King, T., Talaulikar, D., Ng, J. Y., Bryant, A. J., Ridha, Z., Doo, N. W., Menzies, A., et al. (2024) · European Journal Of Haematology · doi:10.1111/ejh.14266 · Cited by 1
Recurrent Cutaneous Manifestation in Multiple Myeloma
Hina, M., Naviwala, S. S., Moosajee, M., & Ali, N. (2024) · BMJ Case Reports · doi:10.1136/bcr-2024-260485 · Cited by 1
Fazio, M., Sorbello, C. M. C., Fabro, V. D., Romano, A., Cannizzaro, M. T., Parrinello, N. L., Esposito, B., Frazzetto, S., Elia, F., Raimondo, F. D., et al. (2024) · Hematology Reports · doi:10.3390/hematolrep16030052 · Cited by 1
Perinephric Extramedullary Disease in Multiple Myeloma
Koichi, A., Zemianschi, R., Manzil, F. F. P., & Eichhorn, J. M. (2024) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000005520 · Cited by 1
Gao, J., Dong, F., Zhang, X., & Jing, H. (2024) · Oncology Letters · doi:10.3892/ol.2024.14745 · Cited by 1
Fenercioğlu, Ö. E., & Çermik, T. F. (2024) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000005546 · Cited by 1
Zhou, L., Liu, D., Du, F., Chen, J., Lu, W., Xiang, H., & Chen, H. (2025) · Oncology Letters · doi:10.3892/ol.2025.14999 · Cited by 1
Extramedullary plasmacytoma of the Gingiva: A rare case report and clinical management
Wei, X., Shen, J., Zheng, S., Dai, H., Li, X., Wu, Z., Bian, Y., Xu, Z., & Liu, P. (2025) · Oral Oncology · doi:10.1016/j.oraloncology.2025.107315 · Cited by 1
Delbart, W., Karfis, I., Vercruyssen, M., de Wind, R., Meuleman, N., Wimana, Z., Flamen, P., & Woff, E. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07500-y · Cited by 1
Hefelfinger, D. C., Sareini, M.-A., & Moore, D. D. (2025) · Arthroplasty Today · doi:10.1016/j.artd.2025.101834 · Cited by 1
Secondary Extramedullary Myeloma of the Gallbladder: A Case Report
Kolagatla, S., Jenkins, J. K., Strunk, H., Smith, F., Ganti, S. S., & Moka, N. (2022) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/23247096221117809 · Cited by 1
Ritka lokalizációjú plasmocytoma autológ hemopoetikus őssejtátültetést követően
Virga, I., Páyer, E., Barna, S. K., Bedekovics, J., Váróczy, L., Virga, B., Nagy, Z., Illés, Á., & Magyari, F. (2023) · Hematológia–Transzfuziológia · doi:10.1556/2068.2023.00173 · Cited by 1
Bemark, M., & Spencer, J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-128-24465-4.00094-6 · Cited by 1
Global Epidemiology, Burden, and Risk Factor of Multiple Myeloma: Past, Present, and FuturePreprint
Zhou, P., Chen, X., Wang, W., Lü, W., Chen, X., Peng, X., Lin, Z., Hua, Q., & Nie, X. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5140918 · Cited by 1
Multiple myeloma (extraosseous manifestations)
Weerakkody, Y. (2013) · Radiopaedia.org · doi:10.53347/rid-22379
Ono, H., Iwatsu, S., Otsuka, E., & Kato, Y. (2022) · Internal Medicine · doi:10.2169/internalmedicine.0035-22
Extramedullary Plasmacytoma Mimicking Gallbladder Cancer
Nishimura, N., Ono, Y., Shirouchi, Y., & Maruyama, D. (2022) · Internal Medicine · doi:10.2169/internalmedicine.1079-22
Shan, J., wang, S., Kang, B., & Lv, S. (2023) · Research Square · doi:10.21203/rs.3.rs-2485853/v1
Adenopathy in Multiple Myeloma: an Enigma Unravelled by FDG PET
Mohite, A., Choudhury, S., Purandare, N. C., Agrawal, T. L., Shet, T. M., Agrawal, A., Shah, S. A., Puranik, A. D., & Rangarajan, V. (2023) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-023-01630-9
[Effects of extramedullary disease on patients with newly diagnosed multiple myeloma].
Yi, T., Jin, S., Wang, Y., Tang, S., Liu, Y. F., Xu, J., Pan, M., Zhang, W. P., & Mi, J. (2023) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2023.01.009
Imaging features of nodular hepatic multiple myeloma localizations: a review of the literature
Coppola, F., Frattoni, P., Mussetto, A. B., BOBBA, G., Fondello, G., Grosso, G., SULCENI, J., Gallo, T., & Cirillo, S. (2023) · Journal of Radiological Review · doi:10.23736/s2723-9284.23.00237-7
Shan, J., Wang, S., Kang, B., & Lv, S. (2023) · International Journal of Surgery Case Reports · doi:10.1016/j.ijscr.2023.108301
RetractedCircumferential gastric wall thickening as initial presentation of relapsed plasma cell leukemia
Koba, Y., Kawata, T., Tamekane, A., & Watanabe, M. (2023) · Clinical Endoscopy · doi:10.5946/ce.2022.291
Intracranial hematolymphoid malignancies: A case series with molecular characterization
Langston, R. G., Pinckard-Dover, H. N., Guzman, G., Wardell, C. P., Gökden, M., Morris, T. W., Day, J. D., & Rodriguez, A. (2023) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2023.107928
Multiple myeloma relapse as extramedullary plasmacytoma of the penis
Coelho, H. G. B., Badior, M., Pinto, P., Ribeiro, A. C. D. M., & Tavares, M. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05464-3
Extramedullary myeloma in the soft tissues of the arm
Karupakula, E. (2023) · Radiopaedia.org · doi:10.53347/rid-178633
The Unfortunate Event - Extramedullary Myeloma Of The Urinary Tract
Woo, W. S. Y., Yee, L. F., Jagwani, A. V., & Ilias, A. S. (2023) · British Journal Of Surgical Science · doi:10.54323/bjoss.2024.31
Rydzewska–Rosołowska, A., Tabor, P., & Hryszko, T. (2024) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16663
Recurrent Cutaneous Manifestation in Multiple Myeloma: A Case Report and Management ApproachPreprint
Naviwala, M. S. S., Hina, M., Moosajee, M., & Ali, N. (2024) · Research Square · doi:10.21203/rs.3.rs-3882128/v1
Case Report: A Rare Cause of Gastric Mass Presenting With An Upper Gastrointestinal Bleed
Williams, S., & Tai, C. (2024) · Endoscopy · doi:10.1055/s-0044-1783615
Unusual painful pelvic masses: Extramedullary hematopoiesis with extramedullary multiple myeloma
Cai, J. X., Varda, M. M., Sin, D., Overby, H., & Yeh, J. J.-C. (2024) · Clinical Case Reports · doi:10.1002/ccr3.8890
Dai, M., Yang, K., Zhang, J., & Zhao, X. (2024) · Asian Journal of Surgery · doi:10.1016/j.asjsur.2024.04.196
Extramedullary Plasmacytoma of the Maxillary Sinuses in a Patient With Multiple Myeloma
Boehler, C., Ozgur, H. T., Le, C. H., & Rogers, S. N. (2024) · OTO Open · doi:10.1002/oto2.144
Liu, P., Wang, Y., Lan, T., & Zhou, C. (2024) · Research Square · doi:10.21203/rs.3.rs-4489552/v1
Metadata
- Authors
- Bladé, J., Beksac, M., Caers, J., Jurczyszyn, A., von Lilienfeld-Toal, M., Moreau, P., Rasche, L., Rosiñol, L., Usmani, S. Z., Zamagni, E., & Richardson, P.
- Affiliations
- Hospital Clínic de Barcelona (ES)
- Centre Hospitalier Universitaire de Liège (BE)
- Jagiellonian University (PL)
- Nantes Université (FR)
- Universitätsklinikum Würzburg (DE)
- Levine Cancer Institute (US)
- Istituto di Ematologia di Bologna (IT)
- Harvard University (US)
- Corresponding author
- Bladé, Joan
- ORCID
- Venue
- Blood Cancer Journal
- Published
- 2022-03-21
- Volume
- 12
- Issue
- 3
- Pages
- 45-45
- ISSN
- 2044-5385 (ISSN-L)
- PMC
- PMC8938478
- OpenAlex
- W4220896277
- Cited by
- 319
- References
- 56
- Citations by year
- 2026: 79 · 2025: 107 · 2024: 73 · 2023: 44 · 2022: 14
- FWCI
- 10.60
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Blood Cancer Journal (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (publishedVersion, cc-by)
- Jagiellonian University Repository (Jagiellonian University) (submittedVersion, cc-by-nc-nd)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- ORBi (University of Liège) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Surgery › Management of metastatic bone disease
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Keywords
- extramedullary disease, multiple myeloma, soft tissue plasmacytoma, hematogenous spread, relapsed/refractory multiple myeloma, central nervous system involvement, leptomeningeal involvement, prognosis, treatment outcomes
- MeSH terms
- Humans, Multiple Myeloma, Neoplasm Recurrence, Local, Plasmacytoma, Prospective Studies, Retrospective Studies, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
